Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments.AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in

Shanghai, China, May 21, 2020 –Eccogene, Inc., a research driven biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition of Michael R. Wiley, Ph.D., to its scientific advisory board.Dr. Wiley earned his PhD in chem

Today Eccogene announces that it has completed a new series financing of more than 100 million RMB, co-led by Oriza Seed and Delos Capital, with participation from new investors HuaGai Capital, Tsing Song Capital and existing investor Sinopharm Capital. The raised fund will support clinical and prec

SHANGHAI,June 17, 2021/PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition ofJacques Mizrahi, Ph.D., to its scientific advisory board.Jacques Mizrahi&n

SHANGHAI,July 28, 2021/PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-se

Shanghai/August.1st, 2022 -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerability, pharmacoki

Boston/Shanghai/November 3rd, 2022 -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mellitus (T2DM). Th

– Proceeds to support the development of Eccogene’s clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disordersBoston/Shanghai/June 12nd, 2023— Eccogene, In